Phase IIb study of cannabidiol for the prevention of acute Graft versus Host Disease GvHD following allogeneic hematopoietic cell transplantation (HCT).

Trial Profile

Phase IIb study of cannabidiol for the prevention of acute Graft versus Host Disease GvHD following allogeneic hematopoietic cell transplantation (HCT).

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Sep 2017

At a glance

  • Drugs Cannabidiol (Primary)
  • Indications Graft-versus-host disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Sep 2017 According to a Kalytera Therapeutics media release, the company has received approval from the Institutional Review Board (IRB) at one of two clinical sites in Israel to commence this study. Kalytera has received approval from the IRB at Beilinson. Results from this trial will support regulatory submission to the FDA. Dr. Yeshurun will be the principal investigator of the study.
    • 07 Sep 2017 Status changed from planning to not yet recruiting according to a Kalytera Therapeutics media release.
    • 14 Aug 2017 According to a Kalytera Therapeutics media release, application of two clinical sites (Rabin Medical Center, Beilinson, and the Rambam Health Care Campus, Haifa) in Israel to commence this study has been submitted to the Institutional Review Boards (IRB).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top